UK biotech Biogen has bolstered its gene therapy portfolio by acquiring Nightstar -based IRD for around $800m in a cash deal. Biogen will gain Nightstar 's adeno-associated virus treatments for inherited retinal disorders ( IRD ). Nightstar has developed candidates for the blindness-inducing X-linked IRDs choroideremia and retinitis pigmentosa, both of which are potential first -in-class therapies. Biogen has been building its range of gene therapies since forming an alliance with IRD in 2018 .
US biotech Biogen has bolstered its gene therapy portfolio by acquiring UK-based Nightstar Therapeutics for around $800m in a cash deal. Biogen will gain Nightstar's adeno-associated virus treatments for inherited retinal disorders (IRD). Nightstar has developed candidates for the blindness-inducing X-linked IRDs choroideremia and retinitis pigmentosa, both of which are potential first-in-class therapies. Biogen has been building its range of gene therapies since forming an alliance with Sangamo in 2014.